PP399 - ASSOCIATIONS BETWEEN INTESTINAL MICROBIOME AND INTESTINAL FAILURE ASSOCIATED LIVER DISEASE IN SHORT BOWEL SYNDROME

PP399

ASSOCIATIONS BETWEEN INTESTINAL MICROBIOME AND INTESTINAL FAILURE ASSOCIATED LIVER DISEASE IN SHORT BOWEL SYNDROME

A. S. Sasdelli^1,*, M. Guidetti¹, C. Cavoli¹, F. Sacilotto¹, C. Pazzeschi¹, F. Sbrega¹, C. Baldo¹, L. Lambertini¹, L. Magnani¹, M. Casoni¹, M. Beretta¹, G. Bartoli¹, S. Cevolani¹, G. Donati¹

¹Center for Chronic intestinal Failure, IRCCS AOUBO, Bologna, Italy

Rationale: In patients with short bowel syndrome (SBS), intestinal microbiome could undergo several alterations due to anatomical, physiological and pharmacological factors. Intestinal failure-associated liver disease (IFALD) represents a potential life-threatening complication for patients with SBS, and preventing measures include intestinal failure-related, parenteral nutrition-related, and systemic-related factors. The aim of the study is to analyze possible associations between the intestinal microbiome and IFALD in patients with SBS in order to identify potential therapeutic targets for the treatment of IFALD.

Methods: Cross-sectional, monocentric study on human fecal samples, carried out on adult patients with SBS, cared at the Chronic Intestinal Failure Centre of Sant’Orsola Hospital, Bologna, Italy. The analyses on fecal samples were performed at the Laboratory of the Microbial Ecology of Health Unit, Department of Pharmacy and Biotechnology, of the University of Bologna.The following were collected: mechanism of CIF, underlying disease; BMI; food intake, PN program, laboratory data, prevalence of IFALD.

Results: 61 patients (women 59%). Clinical data reported as median(IQR): age 51.4(21.8) years, BMI 21.3(4.2) kg/m², PN duration 57.2(74.6) months. SBS-1 49%, IFALD-fibrosis diagnosed by elastography 25%. Associations between IFALD and microbiome: abundance of Lactobacillus (genus), Pasterullaceae (family), Haemophilus (genus), Prevotellaceae (familiy) and Prevotella (genus) and reduction of Lachnospiraceae family (producing butyrate) were associated with IFALD fibrosis.

Conclusion: Specific alteration of the gut microbioma could be observed in SBS patients affected by IFALD, particularly IFALD fibrosis. Future prospective studies are needed to better understand the potential role of the microbiome in the pathogenesis of IFALD.

Disclosure of Interest: None declared